Fig. 3
From: NIR-II nanoprobes in-vivo assembly to improve image-guided surgery for metastatic ovarian cancer
In vivo assembly of NIR-II nanoprobes. a NIR-II fluorescence bioimaging (1000 nm long-pass filter) of the nude mice with murine epidermal tumor by single caudal vein first injection and two-staged in sequence injection (first + second) (interval between two injection is 8 h) under 808 nm excitation (fluence rate = 40 mW cm−2). The concentration of DCNPs in single injection is same to the sum of that for two-staged injection. Liver distribution of nanoprobes (b), tumor targeting efficiency (c), and T/N ratio (d) with single first injection and two-staged in sequence injection, respectively. The red dotted line in d indicates the Rose criterion. (*P < 0.05 vs. first, two-sided Student’s t test). e Fluorescence images of DCNPs-L1(Cy5)-FSHβ + DCNPs-L2(Cy7)-FSHβ (i) and DCNPs-L1(Cy5)-FSHβ + DCNPs-L1(Cy7)-FSHβ (ii) in epidermal tumor of the nude mice and the corresponding harvest organs, blood and tumors (left to right and to bottom: heart, liver, spleen, lung, kidney, tumor, and blood). f T/N ratio of the in vivo assembly (first + second), active targeting (DCNPs-L1-RGD + DCNPs-L2-RGD), passive targeting (DCNPs-L1 + DCNPs-L2), and preassembly (first + second) groups. (*P < 0.05 vs. DCNPs-L1-RGD + DCNP-L2-RGD, two-sided Student’s t test). g Blood circulation and urine excretion of nanoprobes after second injection. The T/N ratio is tumor-to-liver ratio in this epidermal tumor model experiments. All scale bars, 1 cm. Representative images are for n = 5 per group. Mean ± s.d. for n = 5
